n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine has been researched along with cinnarizine in 1 studies
| Studies (n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine) | Trials (n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine) | Recent Studies (post-2010) (n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine) | Studies (cinnarizine) | Trials (cinnarizine) | Recent Studies (post-2010) (cinnarizine) |
|---|---|---|---|---|---|
| 79 | 1 | 16 | 855 | 148 | 190 |
| Protein | Taxonomy | n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine (IC50) | cinnarizine (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.832 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 3.66 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.759 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.444 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 2.513 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.776 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 2.242 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.652 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.083 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.762 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.832 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.167 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.36 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 1.083 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 1.09 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.074 | |
| Mu-type opioid receptor | Homo sapiens (human) | 2.272 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.252 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.731 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.641 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.04 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
1 other study(ies) available for n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine and cinnarizine
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |